Chiasma Inc
FDA rejects Chiasma’s new drug application for therapy to treat rare growth disorder
April 18, 2016Research and Development, Sales and Marketing Chiasma Inc, US FDA, drug trial, rare disease
Shares in Chiasma Inc (Nasdaq: CHMA) plunged to more than halve on the Nasdaq Monday as the company reported the …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
